Study: Medtronic touts increased AF detection with Reveal Linq system

Medtronic (NYSE:MDT) today released 1-year results from a study of patients who experienced a cryptogenic stroke, claiming that its Reveal Linq insertable cardiac monitor was able to detect atrial fibrillation at a greater rate than previously reported in a 2014 clinical trial. Results from the real-world study were presented at the 68th American Academy of Neurology’s annual meeting in Vancouver, Canada. The Reveal Linq device is designed to be implanted beneath the skin on the upper left side of the chest and is indicated for monitoring patients experiencing dizziness, palpitation, fainting or syncope, chest pain and cardiac arrhythmias. Billed as the world’s smallest cardiac monitor, it’s about ⅓ the size of a triple-A battery, Medtronic said, and is designed to work for 3 years using the company’s CareLink network. A total of 1,247 patients were evaluated in the trial, which looked to examine the incidence and duration of AF episodes in a large, real-world population of crypotgenic stroke patients with an ICM. At 1 year, 1,737 AF episodes were detected in 192 patients, returning a 16.3% rate of detection – a 32% relative increase compared to the rate observed in the earlier Crystal AF trial in 2014. “In clinical practice, we continue to see increased AF detection rates using the insertable cardiac monitor compared to the rigorously-controlled Crystal AF study. What’s most significant, however, is that the vast majority of patients had the...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Cardiovascular Clinical Trials Patient Monitoring Medtronic Source Type: news